Allogeneic Umbilical Cord Blood

PreclinicalBiologic

JJoanne Kurtzberg, MD

Allogeneic Umbilical Cord Blood is one of 5 biologic programs targeting Chronic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChronicWithdrawn

ChronicPreclinical

Withdrawn

Competition

Competitive Landscape

5 competitors in Chronic

#DrugCompanyPhaseTrials

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

1 2

Romosozumab

Amgen

Phase 2

2 3

Haldol

DDePuy Orthopaedics

Preclinical

2 4

Pegylated Interferon-Alfa 2a

Vertex Pharmaceuticals

Preclinical

1 5

Allogeneic Umbilical Cord Blood

JJoanne Kurtzberg, MD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebral Palsy1 trial

Mechanism of Allogeneic UCB Therapy in Cerebral Palsy

Completed·—·Phase 1/2·NCT03130816·90 enrolled

Ischemic stroke1 trial

Cord Blood Infusion for Ischemic Stroke

Completed·JJoanne Kurtzberg, MD·Phase 1·NCT02397018·10 enrolled

Chronic1 trial

Allogeneic Umbilical Cord Blood Therapy for Chronic TBI

Withdrawn·—·N/A·NCT01451528

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Allogeneic Umbilical Cord Blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogeneic Umbilical Cord Blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogeneic Umbilical Cord Blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joanne Kurtzberg, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: JJoanne Kurtzberg, MD

Allogeneic Umbilical Cord Blood

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebral Palsy1 trial

Ischemic stroke1 trial

Chronic1 trial

References

Drug Info

Quick Facts

Related News